# To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

> **NCT07406438** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shenzhen Kexing Pharmaceutical Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration (nAMD)

## Interventions

- **DRUG:** GB10

## Key facts

- **NCT ID:** NCT07406438
- **Lead sponsor:** Shenzhen Kexing Pharmaceutical Co., Ltd.
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-12
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07406438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07406438, "To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07406438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*